thereof, wherein the amount of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide, or a salt thereof, is reduced by at least 20% to at least 30% relative to a similar pharmaceutical composition that does not comprise the bioavailability enhancing agent.

9. The pharmaceutical composition of claim 1, wherein the weight ratio of the bioavailability enhancing agent to N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide, or the salt thereof, on a free acid equivalent weight basis is from 1:1 to 1:3.5.

10. The pharmaceutical composition of claim 1, wherein the copovidone is present in an amount of from 10% to 25% by weight of the pharmaceutical composition.

11. The pharmaceutical composition of claim 1, wherein the copovidone is present in an amount of from 10% to 20% by weight of the pharmaceutical composition.

12. The pharmaceutical composition of claim 1 wherein the pharmaceutical composition is a tablet and wherein copovidone is present as an intragranular component.

13. The pharmaceutical composition of claim 1 wherein the solubility of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide as measured by a biphasic dissolution test is at least 30 mcg per mL at 100 minutes.